In summary, this study validates the heterogeneous genomic landscape and affected pathways in MM in a real-world clinical setting, identifies new mutations, such as TYW1, that have not been previously reported in MM, and describes associations of clinical findings and progression-free survival with somatic signatures. This evidence concerns the gene TYW1 and Miyoshi myopathy.